SynthesisBMC infectious diseases2026
Virologic failure and its determinants among HIV patients progress towards the third 95% global target in Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Joint United Nations Program on HIV/AIDS endorsed a new striving 95–95-95 target to end the AIDS epidemic by the end of 2030. This initiative has been implemented by many countries, including Ethiopia, but achieving it requires paramount effort. The purpose of this study was to determine the pooled virologic failure and its determinants using available evidence in Ethiopia.
methodsWe searched available evidence on virologic failure from databases PubMed, Hinari, Cochrane, ScienceDirect, Google Scholar, and other search engines until May 30, 2024. Two authors independently searched articles and extracted them using a Microsoft Excel spreadsheet format. The quality of the studies was evaluated using the Newcastle Ottawa Scale. Heterogeneity among included studies was assessed using the Higgins I2 test statistic. The pooled estimates and its determinants were assessed with a random-effects model using Stata/MP version 17.
resultsWe searched 14,493 relevant records from different databases, and after excluding duplicates, 63 articles were included in this study. The pooled virologic failure was 17.30 (95% CI: 14.57, 20.03, I2 = 99.6). Subgroup analysis indicated that virologic failure prevalence varied by region: it was highest in Southern Ethiopia (26.96%), followed by Oromia region (17.81%). Additional subgroup findings included higher failure in studies conducted after the initiative (18.73%) and among patients under enhanced adherence counseling (43.77%). Poor adherence [OR: 8.10 (95% CI: 4.41, 14.85)], low CD4 count [OR: 2.60 (95% CI: 1.34, 4.99)], advanced WHO clinical staging [OR: 3.99 (95% CI: 2.20, 7.25)], opportunistic infection [OR: 4.91 (95% CI: 2.66, 9.04)], active tuberculosis [OR: 4.54 (95% CI: 1.80, 11.45)], use of cotrimoxazole [OR: 3.13 (95% CI: 1.23, 7.99)], substance use [OR: 4.88 (95% CI: 1.35, 17.62)], and rural residence [OR: 2.88 (95% CI: 1.41, 5.87)] were identified as determinants.
conclusionsVirologic failure was far away from the third 95% target in Ethiopia, with an expected 86% viral suppression. Despite the escalating viral load testing sites and implementation of different programs, the achievement is unacceptably high nationally. This requires innovative strategies, region-specific interventions, and tremendous efforts to meet the global goal by the end of 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.